Christopher Morabito - 01 Aug 2022 Form 4 Insider Report for Astria Therapeutics, Inc. (ATXS)

Role: Chief Medical Officer
Signature: /s/ Ben Harshbarger, as attorney-in-fact for Christopher J. Morabito
Issuer symbol: ATXS
Transactions as of: 01 Aug 2022
Net transactions value: $0
Form type: 4
Filing time: 02 Aug 2022, 08:51:17 UTC
Previous filing: 15 Jul 2022
Next filing: 06 Jun 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATXS	Stock Option (right to buy)	Award	$0	+100,000		$0.000000	100,000	01 Aug 2022	Common Stock	100,000	$3.87	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted on August 1, 2022, pursuant to the Astria Therapeutics, Inc. 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vesting on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.

Content

The option was granted on August 1, 2022, pursuant to the Astria Therapeutics, Inc. 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vesting on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.